Evidence map›Paper›PMID 38502783›Full record

ArticleThe Journal of antimicrobial chemotherapy2024

PHARE: a bioinformatics pipeline for compositional profiling of multiclonal Plasmodium falciparum infections from long-read Nanopore sequencing data.

Salome Hosch, Philipp Wagner, Johanna Nouria Giger, Nina Dubach, Elis Saavedra, Carlo Federico Perno, Jean-Chrysostome Gody, Marilou Sonia Pagonendji, Carine Ngoagouni, Christophe Ndoua and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Salome HoschUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.ORCID 0000-0001-9290-3589
Philipp WagnerUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.ORCID 0000-0002-3589-2796
Johanna Nouria GigerUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.
Nina DubachUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.
Elis SaavedraUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.
Carlo Federico PernoDepartment of Microbiology, Ospedale Pediatrico Bambino Gesù, Piazza di Sant'Onofrio, 4, 00165 Roma, Italy.
Jean-Chrysostome GodyDepartment of Intensive Care, Pediatric University Hospital Centre of Bangui, Bangui, Central African Republic.
Marilou Sonia PagonendjiLaboratory of Parasitology, Institut Pasteur of Bangui, Bangui, Central African Republic.
Carine NgoagouniMedical Entomology Unit, Institut Pasteur of Bangui, Bangui, Central African Republic.
Christophe NdouaNational Malaria Control Program, Ministry of Health, Bangui, Central African Republic.
Christian NsanzabanaUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.ORCID 0000-0002-6944-3892
Ulrich VickosDepartment of Microbiology, Ospedale Pediatrico Bambino Gesù, Piazza di Sant'Onofrio, 4, 00165 Roma, Italy.
Claudia DaubenbergerUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.
Tobias SchindlerUniversity of Basel, Petersplatz 1, 4001 Basel, Switzerland.
Swiss Tropical and Public Health Institute · CHBambino Gesù Children's Hospital · ITInstitut Pasteur de Bangui · CFUniversity of Bangui · CF

Funding

Atlantic Methanol Production CompanyBioko Island Malaria Elimination ProjectGovernment of Equatorial GuineaMarathon EG Production LimitedNoble Energy
6 · The paper itself

Abstract

backgroundThe emergence of drug-resistant clones of Plasmodium falciparum is a major public health concern, and the ability to detect and track the spread of these clones is crucial for effective malaria control and treatment. However, in endemic settings, malaria infected people often carry multiple P. falciparum clones simultaneously making it likely to miss drug-resistant clones using traditional molecular typing methods.

objectivesOur goal was to develop a bioinformatics pipeline for compositional profiling in multiclonal P. falciparum samples, sequenced using the Oxford Nanopore Technologies MinION platform.

methodsWe developed the 'Finding P. falciparum haplotypes with resistance mutations in polyclonal infections' (PHARE) pipeline using existing bioinformatics tools and custom scripts written in python. PHARE was validated on three control datasets containing P. falciparum DNA of four laboratory strains at varying mixing ratios. Additionally, the pipeline was tested on clinical samples from children admitted to a paediatric hospital in the Central African Republic.

resultsThe PHARE pipeline achieved high recall and accuracy rates in all control datasets. The pipeline can be used on any gene and was tested with amplicons of the P. falciparum drug resistance marker genes pfdhps, pfdhfr and pfK13.

conclusionsThe PHARE pipeline helps to provide a more complete picture of drug resistance in the circulating P. falciparum population and can help to guide treatment recommendations. PHARE is freely available under the GNU Lesser General Public License v.3.0 on GitHub: https://github.com/Fippu/PHARE.

Indexed as

Computational BiologyDrug ResistanceMalaria, FalciparumNanopore SequencingPlasmodium falciparumAntimalarialsHumansMutationAntimalarials

Identifiers

PMID38502783
PMCPMC11062946
OpenAlexW4392938479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.